Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
Status:
Completed
Trial end date:
2018-07-05
Target enrollment:
Participant gender:
Summary
FYU-981 or Febuxostat are administrated to hyperuricemia patients (underexcretion and mixed
types) with or without gout for 14 weeks to compare the efficacy and safety of these drugs by
the method of multicenter, randomized, double-blind, ascending dose regimen.